OncologyTube

KEYNOTE-716 Unveiled: Advancing Melanoma Cancer Treatment

admin

Melanoma cancer, a potentially deadly form of skin cancer, is a global concern, with its incidence rates steadily on the rise over the past decades.

As researchers worldwide strive to develop effective treatments for this aggressive disease, certain breakthroughs promise a brighter future for patients. Among these game-changing medical milestones is the KEYNOTE-716 trial, a significant step forward in the journey towards an effective cure for melanoma.

Melanoma develops when the cells responsible for skin pigmentation, called melanocytes, start growing uncontrollably.

While it’s less common than other types of skin cancer, melanoma is more dangerous due to its ability to spread to other parts of the body, a process known as metastasis.

According to the World Health Organization, melanoma accounts for 1% of skin cancer cases but causes the vast majority of skin cancer deaths.

The KEYNOTE-716 trial, aimed at examining the efficacy of Pembrolizumab as adjuvant therapy for high-risk, stage II melanoma, has offered promising results that could revolutionize the way we approach melanoma treatment.

Adjuvant therapy is a treatment given after primary treatment to increase the chances of a cure by killing any remaining cancer cells.

This study focuses on Pembrolizumab, an immunotherapy drug that works by interfering with the way cancer cells shield themselves from the immune system. The American Cancer Society cites immunotherapy as one of the most effective treatment methods for melanoma, further emphasizing the relevance of the KEYNOTE-716 trial in this context.

What is Keynote 716?

The KEYNOTE-716 trial is a groundbreaking study designed to evaluate the effectiveness of Pembrolizumab as an adjuvant therapy for high-risk, stage II melanoma.

But what does this mean, and why is it so important?

Adjuvant therapy refers to additional cancer treatment given after the primary treatment. It’s often used to kill any cancer cells that might have remained undetected in the body. For melanoma patients, adjuvant therapy could mean a significant decrease in the risk of cancer recurrence, a common concern among survivors.

Pembrolizumab, on the other hand, is an immune checkpoint inhibitor, a type of drug that works by blocking proteins on cancer cells or on cells related to the immune system. This blocking action can enable the immune system to attack and kill cancer cells more effectively. Pembrolizumab, marketed under the brand name Keytruda, has been recognized by The U.S. Food and Drug Administration FDA for its efficacy in treating several types of cancer.

Stage II melanoma is characterized by the absence of metastasis to lymph nodes or other parts of the body, but the cancerous growths are larger and may have specific features that make them more likely to spread. This stage of melanoma presents a high-risk factor for patients, necessitating improved treatment strategies.

The KEYNOTE-716 trial, therefore, combines these elements:

This trial’s focus aligns with the medical community’s broader push towards personalized cancer therapy and precision medicine, as noted by the National Cancer Institute, the in-depth exploration of the results of the KEYNOTE-716 trial can contribute substantially to the ongoing evolution of melanoma treatment, shaping our understanding of how immunotherapy can best be utilized in the fight against cancer.

Understanding Pembrolizumab

As we delve further into the heart of the KEYNOTE-716 trial, understanding the star player—Pembrolizumab—is key.

Also known under the brand name Keytruda, is a type of immunotherapy called a checkpoint inhibitor.

The human body naturally has checks and balances—known as checkpoints—that prevent the immune system from attacking its cells. Cancer, in its cunning, can sometimes use these checkpoints to protect itself from the immune response.

Checkpoint inhibitors like Pembrolizumab work by blocking these checkpoints, essentially freeing up the immune system to attack cancer cells more effectively.

Pembrolizumab specifically targets the programmed cell death protein 1 (PD-1) checkpoint on immune system cells called T cells. Cancer cells can often use PD-1 to hide from the immune system. By blocking PD-1, Pembrolizumab allows these immune cells to better recognize and attack cancer cells.

Pembrolizumab can treat a variety of cancers including:

Its application and success in treating diverse cancer types underscore its potential as a powerful tool in the fight against cancer.

But the question remains: Does Pembrolizumab stop cancer from spreading?

While Pembrolizumab and other checkpoint inhibitors have shown significant success in reducing the size of tumors and slowing disease progression, it’s important to note that response to immunotherapy can vary widely among patients.

The Cancer Research Institute emphasizes that while some patients may experience long-term control of cancer, others may not respond to treatment or may develop resistance over time.

However, the KEYNOTE-716 trial specifically studied Pembrolizumab’s efficacy as an adjuvant therapy in preventing the recurrence of high-risk, stage II melanoma. As we’ll explore further, this targeted application of Pembrolizumab resulted in a significant reduction in the risk of disease recurrence or death compared to placebo.

Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials. 

Urothelial carcinoma is the most common type of bladder cancer, and advanced cases are challenging to treat.

Get more infortmation whatching this interview:

 

 

Success Rate and Response to Immunotherapy for Melanoma

Immunotherapy has revolutionized the treatment landscape for many types of cancers, and melanoma is no exception.

In fact, melanoma has been at the forefront of many breakthroughs in immunotherapy.

The implementation of immunotherapy drugs like Pembrolizumab has led to significant improvements in the survival rates and quality of life for melanoma patients.

Immunotherapies work by stimulating or aiding the body’s own immune system to recognize and destroy cancer cells.

Specifically, Pembrolizumab, a type of immunotherapy known as a checkpoint inhibitor, has been demonstrated to significantly improve the survival rates of patients with advanced melanoma.

As per a study by the National Library of Medicine, approximately 34% of advanced melanoma patients treated with Pembrolizumab were alive and well five years after starting the treatment. This is a significant increase compared to the median survival rate of less than one year for advanced melanoma patients before the advent of checkpoint inhibitors.

In the KEYNOTE-716 trial, Pembrolizumab demonstrated its efficacy as an adjuvant therapy for high-risk, stage II melanoma.

Patients treated with Pembrolizumab showed a significant reduction in the risk of disease recurrence or death, demonstrating the substantial impact of this immunotherapy on the success rate of melanoma treatment.

However, it’s essential to understand that not all patients respond to immunotherapy in the same way. The response rate to immunotherapy for melanoma can vary greatly due to several factors, including the specific type and stage of cancer, the overall health of the patient, and the unique genetic characteristics of the cancer itself.

It’s also important to note that while the success rate of Pembrolizumab and other immunotherapies in treating melanoma is promising, these treatments can also cause side effects.

These can range from mild symptoms like fatigue and skin rashes to more serious complications such as immune-related reactions.

Insights into the KEYNOTE-716 Trial

The KEYNOTE-716 trial specifically studied Pembrolizumab as an adjuvant therapy for high-risk, stage II melanoma.

The Trial Design

This double-blind, randomized, placebo-controlled phase 3 study involved a vast array of 160 academic medical centers and hospitals in 16 countries.

Patients aged 12 years or older with completely resected stage IIB or IIC melanoma were part of this study.

The patients were randomly assigned in a 1:1 ratio to receive either Pembrolizumab or a placebo every three weeks for 17 cycles, or until disease recurrence or unacceptable toxicity.

The KEYNOTE-716 Results

The KEYNOTE-716 trial showed that Pembrolizumab as adjuvant therapy resulted in a significant reduction in the risk of disease recurrence or death compared to the placebo.

At the first interim analysis, 54 out of 487 patients in the Pembrolizumab group had a first recurrence of disease or died, compared to 82 out of 489 in the placebo group.

This represented a significant risk reduction and set the stage for Pembrolizumab’s potential efficacy as an adjuvant therapy.

By the second interim analysis, the trial’s results were even more promising, with the Pembrolizumab group showing continued lower rates of recurrence or death compared to the placebo group.

An important aspect of any clinical trial is understanding the safety and side effects associated with the treatment. The KEYNOTE-716 trial’s results showed that Pembrolizumab has a manageable safety profile. While there were grade 3-4 treatment-related adverse events, these were generally manageable and could be effectively treated with appropriate interventions.

These findings from the KEYNOTE-716 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and also have been published in a respected journal, providing a significant addition to the body of literature supporting Pembrolizumab’s use in melanoma treatment.

As an adjuvant therapy, Pembrolizumab might play a crucial role in preventing recurrence in patients with this high-risk disease stage.

The KEYNOTE-716 trial’s findings present a new horizon for melanoma treatment, opening a promising path towards improving survival and reducing disease recurrence.

# What were the Results of KEYNOTE-716?

The KEYNOTE-716 trial results have been a significant milestone in the landscape of adjuvant therapy for melanoma.

To fully grasp the importance of these findings, it’s essential to delve into the specifics of the trial results and understand what they imply for the future of melanoma treatment.

Recurrence-Free Survival Rates

A primary endpoint of the KEYNOTE-716 trial was investigator-assessed recurrence-free survival, defined as the time from randomisation to recurrence or death.

The Pembrolizumab group demonstrated a significant reduction in the risk of disease recurrence or death compared to the placebo group.

At the first interim analysis, the Pembrolizumab group had a significantly lower rate of disease recurrence or death (11% of 487 patients) compared to the placebo group (17% of 489 patients). This pattern persisted at the second interim analysis, with 15% of patients in the Pembrolizumab group and 24% in the placebo group experiencing disease recurrence or death.

Adverse Effects

An integral part of any clinical trial result is the safety profile of the investigated drug.

In the KEYNOTE-716 trial, Pembrolizumab demonstrated a manageable safety profile. Grade 3-4 treatment-related adverse events occurred in 16% of patients in the Pembrolizumab group versus 4% in the placebo group.

Importantly, no deaths due to study treatment occurred.

Interpreting the Results

The results of the KEYNOTE-716 trial revealed that Pembrolizumab as adjuvant therapy for stage IIB or IIC melanoma significantly reduced the risk of disease recurrence or death compared to a placebo.

These promising results suggest that Pembrolizumab may offer a new and effective treatment option for patients with high-risk, completely resected stage II melanoma.

Overall, the results of the KEYNOTE-716 trial are a beacon of hope for patients with high-risk melanoma, suggesting that adjuvant therapy with Pembrolizumab could significantly reduce the risk of disease recurrence.

Is Pembrolizumab an Adjuvant Treatment for Resected Non-Small Cell Lung Cancer?

Pembrolizumab is an immunotherapy drug that has shown remarkable results in treating several types of cancer, including melanoma and non-small cell lung cancer (NSCLC).

While the focus of this article is on the KEYNOTE-716 trial and its implications for melanoma treatment, it’s worth noting that Pembrolizumab has been investigated and utilized in other cancers, particularly NSCLC.

Pembrolizumab and NSCLC

NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer diagnoses.

The use of Pembrolizumab in the treatment of NSCLC has been a topic of significant research interest.

Currently, Pembrolizumab is approved for first-line treatment of metastatic NSCLC in patients whose tumors express PD-L1, as well as a combination therapy with chemotherapy in certain patients.

Adjuvant Treatment in NSCLC

When it comes to the use of Pembrolizumab as an adjuvant treatment for resected NSCLC, clinical trials are underway.

An adjuvant treatment is given after the primary treatment (usually surgery) to lower the risk that the cancer will return. The KEYNOTE-091 (also known as PEARLS) trial is one such study currently investigating Pembrolizumab as a potential adjuvant therapy for resected NSCLC.

Implications for NSCLC Treatment

While results from KEYNOTE-091 and other similar trials are not yet available, the therapeutic potential of Pembrolizumab in this setting is promising.

Success in these trials could significantly enhance the treatment landscape for patients with resected NSCLC, offering a potentially powerful tool for preventing disease recurrence.

For more information on the ongoing trials of Pembrolizumab in NSCLC, you should check ClinicalTrials.gov, an invaluable resource.

Side Effects of Pembrolizumab

While Pembrolizumab has shown significant potential in treating cancers like melanoma and non-small cell lung cancer, as with any therapeutic drug, it does come with its share of potential side effects.

These side effects can range from mild to severe and could affect various parts of the body.

Common Side Effects

Many patients undergoing Pembrolizumab treatment may experience common side effects, though these can vary in their intensity and duration.

Some of the most frequently reported include:

Serious Side Effects

Pembrolizumab, like other immune checkpoint inhibitors, can also cause more serious side effects.

These occur when the drug, designed to stimulate the immune system, triggers an overactive immune response that can inadvertently attack healthy cells in the body. This can lead to inflammation and damage in various organs such as the lungs, intestines, liver, hormone-producing glands, kidneys, or other parts of the body.

If serious side effects develop, your healthcare provider may need to interrupt or completely stop your treatment with Pembrolizumab.

Some of these serious side effects include:

It’s important to remember that not every patient will experience these side effects, and some may experience side effects not listed here.

Regular check-ups with your healthcare provider and open communication about any new or worsening symptoms is essential to managing these potential side effects.

While Pembrolizumab is a potent weapon in the fight against cancer, awareness and management of its potential side effects are essential for optimizing patient outcomes.

Interpreting the KEYNOTE-716 Results

The results of this trial have shone a beacon of hope in the fight against melanoma.

Here, we take a deeper dive into the findings of this study, helping us understand the true implications of these results.

Improved Recurrence-Free Survival

One of the key findings in the KEYNOTE-716 trial was the significant improvement in recurrence-free survival among patients receiving Pembrolizumab as adjuvant therapy.

This result suggests that Pembrolizumab could potentially delay or even prevent the return of melanoma after surgical removal of the tumor.

Disease Recurrence and Death Rates

The KEYNOTE-716 results revealed a marked reduction in the rate of disease recurrence or death in patients receiving Pembrolizumab.

At the first interim analysis, the hazard ratio for disease recurrence or death was 0.65, meaning that the risk was reduced by 35% compared to placebo.

By the second interim analysis, this risk was reduced even further to 39%.

Safety and Side Effects

It’s also important to note that the safety profile of Pembrolizumab was deemed manageable in this study.

Although a higher percentage of patients experienced grade 3-4 treatment-related adverse events compared to the placebo group, the overall safety findings were in line with previous studies and known side effects of Pembrolizumab.

Putting the Results into Perspective

The results of the KEYNOTE-716 trial offer promising evidence that Pembrolizumab can be a valuable addition to the therapeutic arsenal against high-risk, stage II melanoma.

However, these results must be interpreted with some caution.

Despite the improvements seen, Pembrolizumab is not a one-size-fits-all solution, and the treatment plan should be individualized based on the patient’s overall health, disease stage, and potential for side effects.

Also, while the trial focused on melanoma, these results might have implications for other types of cancers as well.

Scientists and researchers are continuing to investigate Pembrolizumab’s potential in treating other types of cancer, including non-small cell lung cancer.

Finally, the KEYNOTE-716 trial provides further proof of the efficacy of immunotherapy in treating cancer. The future of cancer treatment lies not only in traditional chemotherapy but also in harnessing our body’s immune system to fight off the disease.

Jason Luke, MD KEYNOTE-716 trial

For a more in-depth analysis of the KEYNOTE-716 trial, we highly recommend watching the enlightening video interview with Jason Luke, MD, a distinguished expert in melanoma treatment from the University of Pittsburgh Medical Center (UPMC).

In this interview, conducted during the ASCO 2023, Dr. Luke provides a comprehensive review of the phase 3 KEYNOTE-716 study. Don’t miss this opportunity to learn from Dr. Luke’s expertise, and see how these groundbreaking findings may revolutionize the standard of care for patients with earlier-stage melanoma. Watch the interview now:

 

 

Conclusion

The results of the KEYNOTE-716 trial underscore the tremendous potential of pembrolizumab as an adjuvant therapy for patients diagnosed with high-risk, stage IIB or IIC melanoma.

These findings fill a critical knowledge gap in the therapeutic landscape of melanoma, a skin cancer notorious for its aggressive nature and high propensity for metastasis.

In the phase 3 KEYNOTE-716 trial, patients receiving pembrolizumab demonstrated a significant reduction in the risk of disease recurrence or death, underscoring the drug’s profound impact in forestalling the spread of melanoma.

These encouraging results present new hope for melanoma patients and reaffirm the robust efficacy of pembrolizumab, even in earlier stages of the disease.

Exit mobile version